Peptide dosage guides

A selective NNMT inhibitor studied for fat-mass and NAD+ metabolism, with mouse data and mechanistic rationale but no published human outcome trial.

A modified Semax-family research peptide combining terminal acetylation and an adamantane-based design, discussed for memory, learning and neuronal signaling.

A copper-binding hair-support tripeptide studied in follicle and dermal-cell models, with cosmetic relevance but no controlled human scalp-outcome trial.

A growth-hormone-fragment analog studied for fat metabolism, with mostly preclinical support, weak human weight-loss evidence, and regulator and sports concerns.

An EPO-derived tissue-protective peptide studied for small-fiber neuropathy and corneal nerve repair, with small human trials but no approved indication.

A gastric pentadecapeptide studied for gut, wound, vascular, and soft-tissue repair biology, with strong animal data but limited human outcomes.

A synthetic short-peptide bioregulator associated with the airways and investigated for airway-cell maintenance, mucus-barrier function and respiratory symptoms.

A long-acting amylin analog studied for weight management and diabetes, with strongest public evidence in combination with semaglutide and no FDA-approved cagrilintide product.

A synthetic AEDR tetrapeptide in the short-peptide bioregulator family, investigated for heart-muscle cell maintenance and cellular stress responses.

An AED tripeptide studied for cartilage-cell differentiation and age-related cell changes; patient joint benefits remain unproven.

A porcine brain-derived peptide and amino-acid mixture used in some countries for neurologic care, with human stroke and cognition evidence.

A long-acting GHRH analog designed for sustained GH and IGF-1 signaling, with human biomarker evidence but limited outcome data.

A short-acting GHRH analog used for pulse-oriented GH-axis signaling, with indirect human support and limited direct no-DAC outcome evidence.

An angiotensin IV-derived nootropic research molecule studied mostly in preclinical neurotrophic models, with no established human cognitive-treatment evidence.

A delta sleep-inducing neuropeptide studied for sleep architecture, pain, and stress biology, with mixed human relevance and uncertain practical use.

A synthetic pineal bioregulator tetrapeptide studied for telomerase, circadian, and cellular-aging biology, with no proven anti-aging therapy role.

An activin-binding protein with muscle-growth biology and small gene-therapy studies; those findings do not establish an injected-protein regimen.

A D-retro-inverso senolytic research peptide designed to disrupt FOXO4-p53 signaling, with animal evidence and no established human protocol.

Short-pulse GH-axis stack pairing CJC-1295 no DAC, also called Modified GRF 1-29, with Ipamorelin.

A well-characterized copper-binding tripeptide best known for topical skin remodeling, with relevant human data and weaker support for injectable or systemic use.

Focused skin, barrier, and inflammation-support pairing combining GHK-Cu with KPV.

A pralmorelin-family growth-hormone secretagogue that stimulates GH and appetite signaling in human studies, with no FDA-approved U.S. indication and anti-doping restrictions.

An early growth-hormone secretagogue known for GH release and appetite stimulation, with human endocrine studies but no FDA-approved U.S. indication.

An adrenal-tissue-derived peptide complex in the bioregulator family, investigated for adrenal function and adaptation to stress, with uncertain active components.

Recovery-and-skin stack combining BPC-157, TB-500, and GHK-Cu for repair, mobility, and skin-matrix support discussions.

A naturally occurring tripeptide antioxidant central to redox balance and detoxification chemistry, with route-dependent supplementation and skin-pigmentation evidence.

A synthetic GnRH decapeptide used to assess or stimulate the reproductive axis, with strongest evidence in supervised fertility and pituitary-testing contexts.

A placental gonadotropin that activates LH/CG receptors, with strong supervised reproductive-medicine evidence for ovulation triggering and selected male hypogonadism contexts.

A synthetic GHRP-family secretagogue with human GH-release data and preclinical cardiac and metabolic rationale, but limited practical outcome evidence.

A native growth-hormone tail fragment studied in early glucose experiments and laboratory delivery systems; human fat-loss efficacy is unproven.

A mitochondria-derived peptide studied for cytoprotection, neuroprotection, metabolism, and aging biology, with credible research signals but no approved therapy.

A modified IGF-1 analog designed for longer IGF-axis signaling, with mostly preclinical muscle and recovery claims and notable safety uncertainty.

A selective ghrelin-receptor secretagogue with human GH pharmacology and postoperative GI trial data, but limited long-term wellness outcome evidence.

A KISS1-derived neuropeptide that regulates GnRH signaling, with meaningful reproductive-endocrine evidence and protocol-specific fertility and hormone-axis applications.

Broad recovery, skin, and inflammation-support stack combining BPC-157, TB-500, GHK-Cu, and KPV.

An alpha-MSH-derived anti-inflammatory tripeptide studied in gut, skin, wound, and barrier models, with no established human therapeutic indication.

A human cathelicidin antimicrobial peptide central to innate immunity and wound signaling, with topical trial activity and limited systemic-use support.

Long-acting GH-axis stack pairing CJC-1295 DAC with Ipamorelin.

A synthetic alpha-MSH analog and melanocortin agonist with strong disease-specific evidence for EPP photoprotection and more limited cosmetic-tanning data.

A cyclic melanocortin agonist best known for tanning and libido research, with human pigmentation signals and important regulator skin-safety warnings.

A mitochondria-derived peptide linked to metabolic stress signaling, AMPK biology, and exercise adaptation, with early human activity but limited outcome data.

A modified Semax derivative designed for altered stability, with Semax-adjacent neurotrophin rationale but a major direct human-evidence gap.

Direct NAD+—not NMN or NR—with exact compounded vial, nasal-spray, and metered topical presets and limited route-matched human evidence.

Metabolic and mitochondrial concept stack pairing direct NAD+ with MOTS-c and 5-Amino-1MQ.

Nicotinamide riboside with a 300 mg daily oral trial preset and a separately identified 500 mg NR-chloride research vial protocol.

Oral nicotinamide mononucleotide with a human-trial 300 mg daily preset and a distinct identity from direct NAD+ and nicotinamide riboside.

A hypothalamic nonapeptide hormone used as an injectable obstetric medication, with strong supervised-care evidence and broader social-behavior research limits.

A CNTF-derived neurotrophic research peptide studied in Alzheimer and neurogenesis models, with no established human cognitive-treatment evidence.

A palmitoylated AHK tripeptide used in cosmetic hair-support research, with formulation-dependent evidence and no controlled human scalp outcome data.

A topical matrikine-style cosmetic signal peptide used for collagen, elastin, and wrinkle-appearance support, with stronger finished-formula than isolated-peptide evidence.

A PEGylated mechano-growth-factor fragment studied in muscle and repair biology, with preclinical rationale but no proven human muscle-growth outcome.

A short bioregulator tripeptide discussed for neuroprotection, cognition, and age-related biology, with low-confidence preclinical evidence and no established clinical use.

A synthetic KEDP tetrapeptide in the tissue-specific bioregulator family, investigated for prostate-cell activity, inflammation and age-related cellular changes.

A cyclic melanocortin receptor agonist and Vyleesi ingredient, with strong evidence for labeled HSDD use and weaker broader libido data.

A once-weekly GIP/GLP-1/glucagon triple agonist in obesity trials, with strong phase 2 and topline phase 3 weight-loss data but no approved product yet.

A synthetic tuftsin analog studied for anxiety, stress resilience, immune modulation, and cognition-adjacent effects, with limited human evidence.

A well-studied GLP-1 receptor agonist with strong human evidence for weight management, type 2 diabetes, and selected cardiovascular and kidney outcomes.

An intranasal ACTH(4-7) analog studied for cognition, focus, neuroprotection, and stroke recovery, with meaningful evidence limits outside regional clinical use.

Neuropeptide pairing combining Semax with Selank for focus, stress-resilience, and anxiety-oriented discussions.

A GHRH(1-29) fragment that stimulates pituitary GH release, with historical approved-product evidence and limited adult wellness outcome support.

Recombinant human growth hormone with strong evidence for approved pediatric, adult-deficiency, and wasting indications, but not broad anti-aging use.

A mitochondria-targeted tetrapeptide, also known as elamipretide, with strong Barth syndrome evidence and narrower support for general wellness claims.

A thymosin beta-4 fragment discussed for wound, ocular, cardiac, and soft-tissue repair, with limited direct TB-500 human evidence.

A GHRH analog approved for HIV-associated lipodystrophy visceral-fat reduction, with strong human evidence and important glucose, IGF-1, and sports restrictions.

A thymus-derived peptide extract with historical adjunctive human studies and newer immune-cell research; effects depend on the preparation.

A thymic immune-modulating peptide, also called thymalfasin, with meaningful indication-specific clinical evidence in antiviral, immune, and vaccine-response contexts.

Full-length Tβ4 has distinct wound, eye and scalp studies, alongside experimental systemic delivery; results depend on the formulation.

A zinc-dependent thymic hormone with well-described immune biology, historical FTS treatment reports and mostly preclinical therapeutic research.

A thyroid-tissue-derived peptide complex in the bioregulator family, investigated for thyroid function and tissue-specific signaling, with uncertain active components.

A dual GIP/GLP-1 agonist with strong human evidence for obesity, type 2 diabetes, weight maintenance, and obesity-related sleep apnea.

A KED tripeptide studied in vascular cells and small human blood-flow reports, with uncertain benefit and product equivalence.

A vasoactive intestinal peptide studied for pulmonary vascular, lung-injury, and inflammatory signaling contexts, with disease-specific evidence limits.

Two-peptide recovery stack combining BPC-157 with TB-500 for soft-tissue repair, wound-support, and mobility-focused recovery discussions.